Skip to main content

Febrile Neutropenia Risk Assessment Prior to Chemotherapy

CBE ID
2930
1.4 Project
Endorsement Status
1.1 New or Maintenance
Previous Endorsement Cycle
Is Under Review
No
1.3 Measure Description

Percentage of patients with a solid malignant tumor or lymphoma who had a febrile neutropenia (FN) risk assessment completed and documented in the medical record prior to the first cycle of intravenous chemotherapy

        • 1.14 Numerator

          Number of patients who had an FN risk assessment documented in the medical record prior to the first cycle of intravenous chemotherapy.

        • 1.15 Denominator

          Number of patients 18 years of age or older with a solid malignant tumor or lymphoma receiving the first cycle of intravenous chemotherapy.

        • Exclusions

          There are no denominator exclusions.

        • Most Recent Endorsement Activity
          Measure Retired and Endorsement Removed Cancer Spring Cycle 2021
          Initial Endorsement
          Last Updated
          Removal Date
        • Steward
          University of Southern California
          Steward Organization POC Email
          Steward Organization Copyright

          Some proprietary codes are contained in the measure specifications for convenience of the user. Use of these codes may require permission from the code owner or agreement to a license.

          ICD-10 codes are copyrighted © World Health Organization (WHO), Fourth Edition, 2010. CPT © 2010 American Medical Association. CPT is a registered trademark of the American Medical Association. All rights reserved.